earnings
confidence high
sentiment positive
materiality 0.70
Amphastar Q4 net revenue $178.1M, GAAP EPS $0.68; FY revenue $644.4M
Amphastar Pharmaceuticals, Inc.
2023-FY EPS reported
$2.60
revenue$644,395,000
- Q4 2023 net revenue $178.1M (+32% YoY); GAAP net income $36.2M ($0.68 EPS).
- Adjusted non-GAAP Q4 net income $46.9M ($0.88 EPS) vs $37.6M ($0.73 EPS) in Q4 2022.
- Full-year net revenue $644.4M (+29% YoY); GAAP net income $137.5M ($2.60 EPS).
- Full-year adjusted non-GAAP net income $175.7M ($3.32 EPS) vs $103.2M ($1.97 EPS) in FY2022.
- CEO cited strong performance of glucagon, Primatene MIST, BAQSIMI acquisition, and BLA submission for Insulin Aspart.